advertisement

Topcon

Abstract #11678 Published in IGR 7-1

Blood-aqueous barrier changes after the use of prostaglandin analogues in patients with pseudophakia and aphakia: a 6-month randomized trial

Arcieri ES; Santana A; Rocha FN; Guapo GL; Costa VP
Archives of Ophthalmology 2005; 123: 186-192

See also comment(s) by Carl Camras


OBJECTIVES: To investigate the effects of prostaglandin analogues on the blood-aqueous barrier and to evaluate the occurrence of cystoid macular edema in aphakic or pseudophakic patients with glaucoma. METHODS: In this randomized, masked-observer, 6-month clinical trial, patients with primary open-angle, pseudophakic, or aphakic glaucoma were treated once daily with bimatoprost (n = 16), latanoprost (n = 15), or travoprost (n = 17) or twice daily with unoprostone (n = 16) or lubricant drops (control group) (n = 16). Blood-aqueous barrier status, which was assessed using a laser flare meter; intraocular pressure; the occurrence of angiographic cystoid macular edema; and conjunctival hyperemia were evaluated. RESULTS: Mean flare values were significantly higher in the bimatoprost, latanoprost, and travoprost groups throughout follow-up (P < .02). Four latanoprost-treated eyes, 1 bimatoprost-treated eye, and 1 travoprost-treated eye developed cystoid macular edema; all cases resolved after discontinuation of the prostaglandin analogue and treatment with topical diclofenac sodium. Mean intraocular pressure reductions after 6 months were higher for the latanoprost (26%), bimatoprost (28%), and travoprost (29%) groups than for the control (3%) and unoprostone (14%) groups (P < .05). Bimatoprost induced significantly higher hyperemia scores than latanoprost, unoprostone, and placebo (P < .01). CONCLUSION: Bimatoprost, latanoprost, and travoprost use may lead to disruption of the blood-aqueous barrier in patients with pseudophakia and aphakia.

Dr. E.S. Arcieri, Glaucoma Service, Department of Ophthalmology, University of Campinas, Campinas, Sao Paulo, Brazil. rsaran@triang.com.br


Classification:

11.4 Prostaglandins (Part of: 11 Medical treatment)



Issue 7-1

Change Issue


advertisement

Oculus